Principal Investigator:
Study Sponsor: HealthPartners Institute
Location: Neuroscience Center
Purpose of study: Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s dementia. Anxiety in PD is common, has major effects on quality of life and contributes to increased disability. The reported prevalence of anxiety in PD ranges widely and is estimated up to 40%. TMS has been shown to be effective and safe in anxiety and general anxiety disorder (GAD), but there is only limited data available for TMS treatment of anxiety in PD. This study is to assess the feasibility and acceptability of TMS treatment for Anxiety in PD.
Inclusion Criteria
– Idiopathic PD
– Anxiety based on the Parkinson’s anxiety scale
– Between 40 and 90 years old
– Additional inclusion criteria apply. Please contact the study team for more information.
Exclusion Criteria:
– Seizure disorder
– Non-English speaking
– Unable to tolerate imaging or inability to have imaging due to implants or metal
– Additional exclusion criteria apply. Please contact the study team for more information.
Study Contact:
Clarissa Howe
(651) 495-6363
ClinicalTrials@HealthPartners.com
